Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, the Company’s Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place o ...

Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease Results presented today at the H2 Therapeutics Stewardship Meeting in New York City, hosted by the Michael J Fox Foundation Taken together with results from a Phase 2 study that demonstrated orally dosed CNM-Au8 favorably alters critical brai ...

Explains How One Billion-User Global Messaging App Telegram Underpins Their Highly Differentiated Digital Asset Treasury Growth StrategyLAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TON Strategy Company (formerly Verb Technology Company Inc. VERB) (Nasdaq: TONX) (“TONX” or the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that its Executive Chairman Manuel Stotz was interviewed on CNBC’s Squawk Box Asia. The interview, aired live throughout Asia on Wednesd ...

Leadership Team's Technical Primer Enhances Real-World Evidence (RWE) for Cross-Border Impact, Positioning Fifty1 AI Labs in a $48B Market OpportunityVANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN – Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), announces the publication of a landmark technical primer on "transportability" methods in oncology real-world evidence (RWE). Authored by CTO Alind Gupta and CEO Paul Arora, the primer, published in the Journal of Comparative ...

Singapore, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Fitness Champs Holdings Limited (the “Company”), a distinguished aquatic sports education provider in Singapore, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 ordinary shares, 2,000,000 of which are being offered by the Company and 1,750,000 by selling shareholders at a price to the public of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to c ...

Core Viewpoint - Vivani Medical, Inc. is advancing its NPM-139 semaglutide implant program, aiming for Wegovy-level efficacy with less frequent administration, and plans to initiate a Phase 1 clinical study in the first half of 2026, pending regulatory clearance [1][2][3] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [5] - The company is developing a portfolio of GLP-1 based implants targeting chronic weight management and other metabolic diseases, including type 2 diabetes [5] Clinical Development Plans - The Phase 1 study of NPM-139 will assess safety, tolerability, and pharmacokinetics in obese or overweight subjects, with a control arm of low-dose Wegovy injections [3][4] - A Phase 2 study is planned to follow the Phase 1 study, pending results, to evaluate the effects of the semaglutide implant on weight management over 4 to 6 months [4] Market Potential - The GLP-1 market for weight management is experiencing significant growth due to unmet medical needs and improved safety and efficacy profiles of current GLP-1 options compared to previous obesity treatments [2] - NPM-139 is expected to differentiate itself by offering a convenient administration schedule of once or twice a year, potentially improving patient adherence and tolerability [2][6]

Group 1 - SATO Corporation has appointed Matti Peltola as Director of Property Maintenance, effective from August 25, 2025, to enhance expertise in property maintenance and apartment repairs [1][3] - Peltola has a strong background in real estate and construction, having previously worked as a Property Manager at Y-Säätiö and held roles at Caverion and YIT [2] - The Executive Vice President of Housing Business at SATO, Elina Vaurasalo, expressed confidence that Peltola's leadership will improve customer experience and collaboration within the company [3] Group 2 - SATO Corporation is one of Finland's largest rental housing providers, owning approximately 27,000 rental homes in major cities including Helsinki, Tampere, and Turku [4] - The company focuses on providing excellent customer experiences and a diverse range of urban rental housing options, emphasizing sustainable development and stakeholder interaction [5] - SATO is celebrating its 85th anniversary in 2025, highlighting its long-term commitment to profitable and sustainable investments [5]

Core Insights - STRATA Skin Sciences, Inc. has reported growth in partner clinics utilizing its Elevate 360 consulting services platform, which aims to optimize revenue through best practices in marketing, reimbursement, and patient retention [1][2][4] Group 1: E360 Program Impact - The E360 program has been adopted by 99 out of approximately 844 clinics under STRATA's XTRAC usage agreement, leading to an average growth of 7% year over year for participating clinics [4] - A partner clinic that adopted the E360 program expanded from two to nine clinics, resulting in revenue of $61,800 for STRATA in the first half of 2025, indicating significant growth potential [6] Group 2: Business Optimization - The E360 program assists clinics in managing the entire treatment process, from patient referrals to securing insurance reimbursements and scheduling follow-up visits, thereby enhancing patient retention [3][5] - STRATA's initiatives under the E360 program include turn-key marketing solutions and optimization of business systems, which have shown quick improvements in partner clinic financial performance [2][7] Group 3: Market Potential - The company anticipates continued growth opportunities from recent improvements in reimbursement policies that expand treatment indications for XTRAC lasers, including conditions like vitiligo and autoimmune skin disorders [7] - The E360 program is positioned to help clinics meet patient demand and realize market potential, suggesting a strategic focus on enhancing clinic operations and patient care [7]

Core Insights - Palo Alto Networks announced Prisma SASE 4.0, an advanced AI-driven secure access service edge solution that addresses critical security gaps in traditional web protection [1][2][3] - The new solution is designed to neutralize sophisticated web threats in real-time, particularly those that target the browser, which is increasingly becoming the primary interface for enterprise applications [2][3] Company Developments - Prisma SASE 4.0 includes innovations such as in-browser advanced web protection that identifies and neutralizes malware before it can cause harm, providing a critical layer of defense [2][3] - The company reported a significant growth in SASE annual recurring revenue (ARR), reaching $1.3 billion in fiscal year 2025, which represents a 35% year-over-year increase, outpacing the overall market growth [3][6] - Palo Alto Networks has been recognized as a Leader in the Gartner Magic Quadrant for SASE Platforms for three consecutive years, indicating strong market leadership and innovation [3][10] Industry Context - The shift towards browser-based applications necessitates enhanced security measures, as traditional consumer-grade browsers lack the necessary controls to combat rising cyber threats [2][3] - The introduction of AI-augmented data classification in Prisma SASE 4.0 aims to reduce false positives significantly, achieving 10 times fewer than traditional methods, which is crucial for protecting sensitive corporate data [7] - The new Private App Security feature adapts to protect dynamic applications, addressing the limitations of older static rule-based web application firewalls [7]

Company Overview - ZenaTech, Inc. is a business technology solution provider specializing in AI drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions [6][7] - The company has been operational since 2017, focusing on software development and drone design to enhance customer processes in various sectors including law enforcement, health, government, and industrial applications [6][8] Upcoming Events - ZenaTech will participate in multiple investor conferences across the US and a European roadshow over the next two months, providing opportunities for presentations and one-on-one meetings with institutional investors [1] - Key events include the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, and the ArcStone-Kingswood Growth Summit 2025 [2] - The European Investor Roadshow will take place on September 18, 2025, in major German financial hubs, where ZenaTech's executives will discuss the company's growth strategy [3] Product and Service Development - The company is focusing on the rollout of its Drone as a Service business, advancements in commercial drone solutions, and developments in its US defense business [1] - ZenaDrone, a subsidiary of ZenaTech, specializes in autonomous drone solutions that integrate machine learning, AI, and Quantum Computing for various applications including agriculture and defense [8]